DJIA 16,987.51 -61.49 -0.36%
NASDAQ 4,567.60 -24.21 -0.53%
S&P 500 1,985.54 -11.91 -0.60%
market minute promo

Dendreon Corp (NASDAQ: DNDN)



company name or ticker
Company Photos
(Click to zoom)

Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014

Cancer immunotherapy vaccine developer Inovio Pharmaceuticals has largely underperformed the market in 2014. Find out what's keeping the stock down and whether or not Inovio shares are poised for a rebound.

Medivation Eyes Blockbuster As Cancer Drug Gets An OK

Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca

Medivation and Astellas get expanded FDA approval for Xtandi with a label that looks better than Johnson & Johnson's Zytiga.

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

MannKind Corp. And The Folly Of Cult Biotech Stocks

Aug. 18 Premarket Briefing: 10 Things You Should Know

Ebola Vaccine and Inhaled Insulin Incoming

Biotech partnerships, an IPO that wasn't, and how big data is fighting Ebola.

A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio

Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog

Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog

Dendreon: Is The End Near?

See More Articles...